Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.

Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.